Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer von Baselga, José, Lewis Phillips, Gail D, Verma, Sunil, Ro, Jungsil, Huober, Jens, Guardino, Alice E, Samant, Meghna K, Olsen, Steve, de Haas, Sanne L, Pegram, Mark D

Volltext

Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation von Wang, Jing-Hung, Forterre, Alexis V, Zhao, Jinjing, Frimannsson, Daniel O, Delcayre, Alain, Antes, Travis J, Efron, Bradley, Jeffrey, Stefanie S, Pegram, Mark D, Matin, A C

Volltext

HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors von Pegram, Mark D., Miles, David, Tsui, C. Kimberly, Zong, Yu

Volltext

Extracellular Vesicle-Mediated In Vitro Transcribed mRNA Delivery for Treatment of HER2(+) Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity von Forterre, Alexis, Wang, Jing-Hung, Delcayre, Alain, Kim, Kyuri, Green, Carol, Pegram, Mark D., Jeffrey, Stefanie S., Matin, A. C.

Volltext

Role of Fcγ receptors in HER2-targeted breast cancer therapy von Musolino, Antonino, Gradishar, William J, Rugo, Hope S, Nordstrom, Jeffrey L, Rock, Edwin P, Arnaldez, Fernanda, Pegram, Mark D

Volltext

Single-cell immunoblotting resolves estrogen receptor-α isoforms in breast cancer von Kim, John J., Liang, Wenchuan, Kang, Chi-Chih, Pegram, Mark D., Herr, Amy E.

Volltext

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer von WOLFF, Antonio C, HAMMOND, M. Elizabeth H, MCSHANE, Lisa M, PAIK, Soonmyung, PEGRAM, Mark D, FEREZ, Edith A, PRESS, Michael F, RHODES, Anthony, STURGEON, Catharine, TAUBE, Sheila E, TUBBS, Raymond, VANCE, Gail H, SCHWARTZ, Jared N, VAN DE VIJVER, Marc, WHEELER, Thomas M, HAYES, Daniel F, HAGERTY, Karen L, ALLRED, D. Craig, COTE, Richard J, DOWSETT, Mitchell, FITZGIBBONS, Patrick L, HANNA, Wedad M, LANGER, Amy

Volltext

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells von KONECNY, Gottfried E, PEGRAM, Mark D, KEITH, Barry R, GILMER, Tona M, BERGER, Mark, PODRATZ, Karl C, SLAMON, Dennis J, VENKATESAN, Natarajan, FINN, Richard, GUORONG YANG, RAHMEH, Martina, UNTCH, Michael, RUSNAK, David W, SPEHAR, Glenn, MULLIN, Robert J

Volltext

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Ampli... von VALERO, Vicente, FORBES, John, FUMOLEAU, Pierre, ROLSKI, Janusz, MRSIC-KRMPOTIC, Zrinka, JAGIELLO-GRUSZFELD, Agnieszka, RIVA, Alessandro, BUYSE, Marc, TAUPIN, Henry, SAUTER, Guido, PRESS, Michael F, SLAMON, Dennis J, PEGRAM, Mark D, PIENKOWSKI, Tadeusz, EIERMANN, Wolfgang, VON MINCKWITZ, Gunter, ROCHE, Henri, MARTIN, Miguel, CROWN, John, MACKEY, John R

Volltext

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer von Wolff, Antonio C, Hammond, M Elizabeth H, Schwartz, Jared N, Hagerty, Karen L, Allred, D Craig, Cote, Richard J, Dowsett, Mitchell, Fitzgibbons, Patrick L, Hanna, Wedad M, Langer, Amy, McShane, Lisa M, Paik, Soonmyung, Pegram, Mark D, Perez, Edith A, Press, Michael F, Rhodes, Anthony, Sturgeon, Catharine, Taube, Sheila E, Tubbs, Raymond, Vance, Gail H, van de Vijver, Marc, Wheeler, Thomas M, Hayes, Daniel F

Volltext

Docetaxel, Cisplatin, and Trastuzumab As Primary Systemic Therapy for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced Breast Cancer von HURLEY, Judith, DOLINY, Philomena, REIS, Isildinha, SILVA, Orlando, GOMEZ-FERNANDEZ, Carmen, VELEZ, Pedro, PAULETTI, Giovanni, PEGRAM, Mark D, SLAMON, Dennis J

Volltext

Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status von GORDON, Michael S, MATEI, Daniela, COHN, David E, ROMAN, Lynda, DERYNCK, Mika K, NG, Kimmie, LYONS, Benjamin, ALLISON, David E, EBERHARD, David A, PHAM, Think Q, DERE, Randall C, KARLAN, Beth Y, AGHAJANIAN, Carol, MATULONIS, Ursula A, BREWER, Molly, FLEMING, Gini F, HAINSWORTH, John D, GARCIA, Agustin A, PEGRAM, Mark D, SCHILDER, Russell J

Volltext

Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients von KONECNY, Gottfried E, MENG, Y. Gloria, BERYT, Malgorzata, HEPP, Hermann, SLAMON, Dennis J, PEGRAM, Mark D, UNTCH, Michael, WANG, He-Jing, BAUERFEIND, Ingo, EPSTEIN, Melinda, STIEBER, Petra, VERNES, Jean-Michel, GUTIERREZ, Johnny, KYU HONG

Volltext

Clinical validation of an immunohistochemistry‐based CanAssist‐Breast test for distant recurrence prediction in hormone receptor‐positive breast cancer patients von Bakre, Manjiri M., Ramkumar, Charusheila, Attuluri, Arun Kumar, Basavaraj, Chetana, Prakash, Chandra, Buturovic, Ljubomir, Madhav, Lekshmi, Naidu, Nirupama, R, Prathima, Somashekhar, S. P., Gupta, Sudeep, Doval, Dinesh Chandra, Pegram, Mark D.

Volltext

Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer von STORNIOLO, Anna Maria, PEGRAM, Mark D, PANDITE, Lini, FLEMING, Ronald A, LEBOWITZ, Peter F, HO, Peter T. C, BURRIS, Howard A, OVERMOYER, Beth, SILVERMAN, Paula, PEACOCK, Nancy W, JONES, Suzanne F, LOFTISS, Jill, ARYA, Nikita, KOCH, Kevin M, PAUL, Elaine

Volltext

Mitochondrial copper depletion suppresses triple-negative breast cancer in mice von Cui, Liyang, Gouw, Arvin M., LaGory, Edward L., Guo, Shenghao, Attarwala, Nabeel, Tang, Yao, Qi, Ji, Chen, Yun-Sheng, Gao, Zhou, Casey, Kerriann M., Bazhin, Arkadiy A., Chen, Min, Hu, Leeann, Xie, Jinghang, Fang, Mingxi, Zhang, Cissy, Zhu, Qihua, Wang, Zhiyuan, Giaccia, Amato J., Gambhir, Sanjiv Sam, Zhu, Weiping, Felsher, Dean W., Pegram, Mark D., Goun, Elena A., Le, Anne, Rao, Jianghong

Volltext

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers von Sikic, Branimir I, Lakhani, Nehal, Patnaik, Amita, Shah, Sumit A, Chandana, Sreenivasa R, Rasco, Drew, Colevas, A Dimitrios, O'Rourke, Timothy, Narayanan, Sujata, Papadopoulos, Kyriakos, Fisher, George A, Villalobos, Victor, Prohaska, Susan S, Howard, Maureen, Beeram, Muralidhar, Chao, Mark P, Agoram, Balaji, Chen, James Y, Huang, Jie, Axt, Matthew, Liu, Jie, Volkmer, Jens-Peter, Majeti, Ravindra, Weissman, Irving L, Takimoto, Chris H, Supan, Dana, Wakelee, Heather A, Aoki, Rhonda, Pegram, Mark D, Padda, Sukhmani K

Volltext

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance von Upton, Rosalynd, Banuelos, Allison, Feng, Dongdong, Biswas, Tanuka, Kao, Kevin, McKenna, Kelly, Willingham, Stephen, Ho, Po Yi, Rosental, Benyamin, Tal, Casp Michali, Raveh, Tal, Volkmer, Jens-Peter, Pegram, Mark D., Weissman, Irving L.

Volltext

Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature revi... von Müller, Volkmar, Bartsch, Rupert, Lin, Nancy U., Montemurro, Filippo, Pegram, Mark D., Tolaney, Sara M.

Volltext

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer von Pegram, Mark D., Hamilton, Erika P., Tan, Antoinette R., Storniolo, Anna Maria, Balic, Kemal, Rosenbaum, Anton, Liang, Meina, He, Peng, Marshall, Shannon, Scheuber, Anita, Das, Mayukh, Patel, Manish R.

Volltext